DSpace Общество:

Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure - Relevance to Inflammatory Cytokines and Outcomes

2026-05-14T07:45:39Z

Название: Apoptotic Microparticles as Predicted Biomarkers in Patients with Chronic Heart Failure - Relevance to Inflammatory Cytokines and Outcomes Авторы: Berezin, A. E.; Kremzer, A. A.; Martovitskaya, Yu. V.; Березін, Олександр Євгенійович; Кремзер, Олександр Олександрович Аннотация: Aim: To evaluate the relevance of endothelial-derived apoptotic microparticles (EMPs) with inflammatory cytokine outcomes in patients with ischaemic chronic heart failure (CHF). Methods: A total of 154 patients with moderate-to-severe CHF were enrolled in the study. Flow cytometry analysis was used for quantifying the number of EMPs. All-cause mortality, CHF-related death, and CHD-readmission rates were examined. Results: During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively. Medians of circulating EMPs in survivor and non-survivor patient cohorts were 0.286 n/mL (95% CI = 0.271-0.309 n/mL) and 0.673 n/mL (95% CI = 0.65-0.74 n/mL) (P<0.001). There was a significantly lower concentration of sRANKL, OPG, TNF-alpha, sFAS, and sFAS ligand in the survivor patients when compared with those who met composed endpoints. The sFAS/sFAS ligand ratio in the non-survivor patient cohort was significantly higher than in the survivor cohort (P<0.001). In multivariate model EPMs, NYHA class, NT-pro-BNP, TNF-alpha, sFAS/sFAS ligand ratio, and OPG remained statistically significant for the cumulative endpoint: all-cause mortality, CHF-related death, and CHF-related readmission. Conclusion: Increased apoptotic circulating EMPs, OPG, and FAS-sFAS ligand ratio independently predicted cumulative survival in CHF patients.

Impaired Immune Phenotype of Endothelial Cell-derived Micro Particles: The Missing Link between Diabetes-related States and Risk of Cardiovascular Complications?

2026-05-04T11:21:46Z

Название: Impaired Immune Phenotype of Endothelial Cell-derived Micro Particles: The Missing Link between Diabetes-related States and Risk of Cardiovascular Complications? Авторы: Berezin, A. E.; Березін, Олександр Євгенійович Аннотация: Type two diabetes mellitus (T2DM) remains a leading contributor to cardiovascular (CV) mortality worldwide. Although obese and metabolic syndrome are discussed key factors contributing a higher risk of T2DM, the exact molecular mechanisms underlying to the progression of dysmetabolic states are still not completely clear. There is large body of evidence regarding endothelial dysfunction as a key player in increasing CV risk and that vascular damage in the dysmetabolic patients might mediate through an imbalance between various populations of micro particle (MP). The short commentary is discussed a role of impaired ratio between apoptotic MPs and activated MPs derived from endothelial cells that was recognized as “impaired phenotype” of endothelial cell-derived MPs. It has considered the causality epigenetic reprogramming, metabolic disorders, inflammation, and oxidative stress in forming of “impaired phenotype” of MPs. The incorporation of measurement of the endothelial cell-derived MP number into a conventional CV risk factor model aimed improving of risk stratification of the dysmetabolic patients with high probability of CV disease is discussed.

Патогенетичне лікування хворих на гіпертонічну хворобу залежно від рівня активності симпатоадреналової системи

2026-05-01T07:07:30Z

Название: Патогенетичне лікування хворих на гіпертонічну хворобу залежно від рівня активності симпатоадреналової системи Авторы: Алипова, Олена Євгенівна; Мочоний, Валентин Олександрович; Кузнєцова, Л. П.; Проценко, Н. М.; Васильченко, О. Ю.; Alypova, O. E.; Mochonyi, V. O.; Kuznetsova, L. P.; Protsenko, N. M.; Vasylchenko, O. Y. Аннотация: Мета роботи. Порівняльна оцінка впливу комплексного лікування із застосуванням бісопрололу або амлодипіну на показники активності симпатичної нервової системи у хворих на гіпертонічну хворобу ІІ стадії. Матеріали та методи. Проведено комплексне клініко-параклінічне дослідження 121 пацієнтів з гіпертонічною хворобою ІІ стадії. Оцінювали стан активності симпатоадреналової системи за рівнями добової уроекскреції катехоламінів: адреналіну, норадреналіну, діоксифенілаланіну (ДОФА), дофаміну – на початку та через 6 місяців після проведеного лікування. Purpose of the study. Recently, new opportunities to optimize clinical efficacy and tolerability of treatment of patients with essential hypertension appeared. Determination of the indicators of increased activity of the sympathetic nervous system (SNS) in practice could contribute to differentiated treatment of patients with hypertension. Comparative estimation of influence of complex treatment with bisoprolol or amlodipine on the SNS activity parameters in patients with arterial hypertension (AH) of II stage. Materials and methods. 121 patients (men and women) with documented II stage AH were examined clinically. Concentrations of adrenaline, noradrenaline, dopamine and DOPA in urine were evaluated by spectrochromatography, endotheliumdependent vasodilation was studied using complex rheographic ReoCom Professional (HAI-Medicom, Ukraine). Patients were divided into 2 groups: if concentration of noradrenalin in urine exceeds healthy subjects levels more than on 20% – patients were added to basic treatment (enalapril, atorvastatin, aspirin) bisoprolol, if concentration of noradrenalin in urine exceeds healthy subjects levels less than on 20% – we added amlodipine. Statistic analysis was done on Apache OpenOffice (version 4.1) and PSPP (version 0.7.9).

Прогностичне значення генетичної гетерогенності aпo-Е в формуванні дисліпідемії у хворих на гіпертонічну хворобу

2026-05-01T07:00:36Z

Название: Прогностичне значення генетичної гетерогенності aпo-Е в формуванні дисліпідемії у хворих на гіпертонічну хворобу Авторы: Буряк, Віктор Валерійович; Деміденко, Олександр Вікторович Аннотация: Мета: Визначення генетичних детермінант формування ліпідних аберацій у хворих на ГХ.